Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 125B 83.02M 71.95M 68M 61.74M 116M 7.96B 116M 812M 314M 4.04B 312M 305M 12.88B P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 356B 236M 205M 194M 176M 329M 22.67B 331M 2.31B 893M 11.5B 888M 868M 36.64B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
08-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-11 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
05-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
07/08/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/05/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/05/25 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/03/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/11/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/08/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
06/05/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/03/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
1 day-0.96%
1 week-2.21%
Current month-3.73%
1 month-0.32%
3 months-0.96%
6 months-9.88%
Current year-21.52%
1 week 1,505
Extreme 1505
1,620
1 month 1,495
Extreme 1495
1,635
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.96%-2.21%+42.86%+184.93% 83.82M
+0.15%+1.21%+48.79%+97.65% 1,013B
+0.03%+0.07%+51.47%+65.55% 644B
-0.20%+4.62%+21.39%+72.57% 465B
+0.53%+4.26%+40.29%+38.70% 352B
+0.39%+2.35%+17.96%+23.87% 264B
+0.17%+4.17%+6.96%+10.93% 253B
+0.19%-3.81%+37.81%+44.35% 203B
-1.20%-5.64%-24.09%-59.10% 188B
+0.94%+1.39%+33.21%+95.16% 181B
Average +0.00%-0.65%+27.67%+57.46% 356.38B
Weighted average by Cap. +0.11%+0.32%+34.33%+59.68%

Financials

2024 2025
Net sales 91.79B 60.89M 52.77M 49.87M 45.28M 84.86M 5.84B 85.36M 595M 230M 2.96B 229M 224M 9.44B 127B 84.06M 72.84M 68.85M 62.51M 117M 8.06B 118M 822M 318M 4.09B 316M 309M 13.04B
Net income 23.85B 15.82M 13.71M 12.96M 11.76M 22.04M 1.52B 22.17M 155M 59.76M 770M 59.42M 58.1M 2.45B 3.09B 2.05M 1.77M 1.68M 1.52M 2.85M 196M 2.87M 20.03M 7.74M 99.66M 7.69M 7.52M 318M
Net Debt 134B 88.65M 76.82M 72.61M 65.92M 124M 8.5B 124M 867M 335M 4.31B 333M 326M 13.75B 231B 153M 133M 126M 114M 214M 14.7B 215M 1.5B 579M 7.46B 576M 563M 23.77B
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
16/09/26 ARS 1,550.00 -0.96% 374
15/09/26 ARS 1,565.00 -0.63% 8,455
14/09/26 ARS 1,575.00 +0.64% 1,851
11/09/26 ARS 1,565.00 0.00% 394
10/09/26 ARS 1,565.00 -1.26% 703
  1. Stock Market
  2. Stocks
  3. RICH Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!